Stereotactic body radiation therapy for liver metastasis from colorectal cancer: size matters

Flamarique, S.; Campo, M.; Asin, Gemma; Pellejero, S.; Viúdez, A.; Vega, F. Arias de la

doi:10.1007/s12094-020-02375-x

Cited by 11 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Andratschke et al reported that smaller treated metastatic tumor volume, as observed in the study where the GTV volume ranged from a minimum of 0.6 cc to a maximum of 699 cc (median volume of 27 cc), and the PTV volume ranged from a minimum of 4.5 cc to a maximum of 1074.0 cc (median volume of 71.3 cc), were found to be a significant predictor for LC (p < 0.001) [12]. Furthermore, Flamarique et al reported that tumor volumes > 30 cc correlated with worsened two-year LC rates (90% vs. 34.5%) (p = 0.005) [73].…”

Section: Number Size and Volume Of Metastatic Liver Lesionsmentioning

confidence: 97%

Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century

Mheid,

Allen,

et al. 2023

Current Oncology

View full text Add to dashboard Cite

The utilization of stereotactic body radiation therapy for the treatment of liver metastasis has been widely studied and has demonstrated favorable local control outcomes. However, several predictive factors play a crucial role in the efficacy of stereotactic body radiation therapy, such as the number and size (volume) of metastatic liver lesions, the primary tumor site (histology), molecular biomarkers (e.g., KRAS and TP53 mutation), the use of systemic therapy prior to SBRT, the radiation dose, and the use of advanced technology and organ motion management during SBRT. These prognostic factors need to be considered when clinical trials are designed to evaluate the efficacy of SBRT for liver metastases.

show abstract

Section: Number Size and Volume Of Metastatic Liver Lesionsmentioning

confidence: 97%

Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century

Mheid,

Allen,

et al. 2023

Current Oncology

View full text Add to dashboard Cite

show abstract

“…Das relativ neue Konzept der Oligometastasierung hat etablierte onkologische Prinzipien der Behandlungsplanung in den letzten Jahren spürbar verändern können 1 3 5 . Die bisherigen Unterscheidungen zwischen noch lokalisierten Tumormanifestationen und bereits disseminiertem, systemischen Befall werden dabei eher fließend gesehen 5 .…”

Section: Oligometastasierungunclassified

“…In einer solchen Situation kann eine Lokaltherapie, wie z. B. die stereotaktische Bestrahlung dieser einzelnen Metastasen, in Ergänzung der Systemtherapie sinnvoll sein 1 3 5 7 .…”

Section: Oligometastasierungunclassified

“…Die Prognose des synchron metastasierten Kolonkarzinoms ist in diesem Krankheitsstadium leider immer noch nicht zufriedenstellend. Dennoch kann ein frühes „downsizing“ von Lebermetastasen durch intensive Systemtherapie und eine dadurch in einigen Fällen erreichte Operabilität, wie im hier vorgestellten Fall, einen Zugewinn an therapiefreier Zeit und eine verbesserte Lebenserwartung erreichen 1 9 .…”

Section: Komplementäre Therapieunclassified

See 1 more Smart Citation

And the beat goes on … – stereotaktische Bestrahlung von inoperablen Lebermetastasen eines Kolonkarzinoms: Innovatives Konzept bei Oligometastasierung

Holzhauer¹

2022

Deutsche Zeitschrift für Onkologie

View full text Add to dashboard Cite

ZusammenfassungMit der hier vorgestellten Kasuistik wird der Krankheitsverlauf eines Patienten mit synchron hepatisch metastasiertem Sigmakarzinom erneut aufgegriffen. Der ungewöhnliche Erkrankungs- und Behandlungsverlauf machte es möglich, diesen Patienten mehrfach vorzustellen. Nach dem initialen Konzept der neoadjuvanten Systemtherapie mit noch kurativem Ansatz, wird heute in der Situation einer hepatischen Oligometastasierung der moderne Einsatz der Körperstereotaxie beschrieben. Begleitet wird diese innovative Behandlungsmaßnahme durch geeignete Maßnahmen der supportiven Komplementärmedizin.

show abstract

“…Всем больным, включенным в исследования, проводили КТ-разметку и волюметрию печени, однако рекомендованная некоторыми исследователями [16] терапия проводилась в соответствии с общими принципами проведения SBRT, различия методологического свойства не являлись определяющими. В нашей группе пациентов брюшная компрессия применялась у 24 (40 %) больных, у остальных 36 (60 %) пациентов процедура выполнялась с задержкой дыхания на вдохе под контролем системы RPM.…”

Section: конечные точки и методики оценкиunclassified

Experience with stereotactic r adiation therapy for liver oligometastases of colorectal cancer

et al. 2022

View full text Add to dashboard Cite

Introduction: The problem of treating patients with unresectable liver metastases of colon cancer is currently far f rom being solved. One possible approach is the use of stereotactic body radiotherapy.The purpose of this study was to evaluate the immediate and long-term results of stereotactic radiotherapy in patients with colorectal cancer and oligometastatic liver metastases.Methods: This study was designed as a retro-prospective, open-label, controlled, non-randomized clinical trial. We assessed one-year local control, one-year overall survival, progression-free survival, and toxicity in 60 patients with oligometastatic liver disease from colorectal cancer who underwent stereotactic body radiotherapy, with median dose of 54 Gy.Results: The median follow-up was 20,1 months. One-year local control (LC) was 73,7 % (95 % CI = 62,7–86,6 %). Oneyear overall survival (OS) was 92,8 % (95 % CI = 86,3–99,9 %), one-year progression-free survival (PFS) was 31,3 % (95 % CI = 21,1–46,4 %) with a median of 8,1 months. Grade ≥ 3 toxicity was not noted. No cases of radiation-induced liver failure were observed. Radiation dose (HR = 0.88, 95 % CI = 0.81–0.95, p = 0.00087), metastasis size (HR = 1.51, 95 % CI = 1.07–2.12, p = 0.01858) and their number (HR = 1.8, 95 % CI = 1.01–3.22, p = 0.04669) are significant risk factors for LC. Metastasis size > 3 cm is a significant risk factor for LC (HR = 5.5, 95 % CI = 1.7–17.9, p = 0.005) and OS (HR = 3.8, 95 % CI = 1.3–11.7, p = 0.02).Conclusion: Stereotactic body radiotherapy is an effective and safe method of providing local control of oligometastatic liver metastases in colorectal cancer as part of a combined treatment approach. Further studies are required to individualize the indications for this treatment method.

show abstract

Stereotactic body radiation therapy for liver metastasis from colorectal cancer: size matters

Cited by 11 publications

References 30 publications

Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century

Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century

And the beat goes on … – stereotaktische Bestrahlung von inoperablen Lebermetastasen eines Kolonkarzinoms: Innovatives Konzept bei Oligometastasierung

Experience with stereotactic r adiation therapy for liver oligometastases of colorectal cancer

Contact Info

Product

Resources

About